Day: October 20, 2022

– First presentation of BPT264, the only Treg-targeting IL-2 for autoimmune disease that is both IL2Rα-enhanced and IL2Rβ-dead, displaying best-in-class preclinical properties —

– Introduction of BPT323, a cutting-edge, multifunctional immunocytokine combining TNFα blockade and selective T_reg expansion for the treatment of autoimmune disease —

SAN DIEGO and BASEL, Switzerland, Oct. 20, 2022 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a privately held biotechnology company developing next-generation multifunctional precision immunotherapies, today announced the presentation of two posters showcasing the potential of its unique chemical protein engineering platform at the 10^th International Conference on Autoimmunity: Mechanisms and Novel Treatments taking place October 20-25, 2022, in Chania, Crete.

“We are excited to share, for the first time, details of our innovative IL-2-based therapeutics that selectively activate and enhance Treg expansion for the treatment of patients with autoimmune diseases,” said Dr. Bertolt Kreft, Chief Scientific Officer of Bright Peak Therapeutics. Tregs are essential for maintaining peripheral tolerance, preventing autoimmunity and limiting chronic inflammatory diseases. IL-2 is an essential cytokine critical for Treg activation and proliferation, and low-dose IL-2 has demonstrated promising preliminary clinical efficacy in several autoimmune diseases.

Dr. Kreft continued, “Our chemical protein synthesis platform enabled us to create an optimized IL-2 payload that is uniquely IL2Rα-enhanced as well as IL2Rβ-dead, with the further capacity to be chemically conjugated. Using this fully synthetic IL-2 payload, we created a PEGylated, half-life-extended molecule with best-in-class preclinical properties as well as a cutting-edge multifunctional immunocytokine combining TNFα blockade and selective Treg expansion.”

Details of the abstracts are as follows:

Dates and Times: October 21-24, 2022, 10:00 AM – 11:30 AM (CET)

Title: Identification of BPT264 – a potent alpha-enhanced/beta-dead and half-life-extended IL-2 Treg enhancer for treatment of autoimmune diseases

Abstract Highlights: Using our chemical protein synthesis technology, we rationally designed an enhanced cytokine payload harboring a site-specific chemical conjugation handle and specific sequence variations that retune the biological properties of IL-2 for the treatment of patients with autoimmune disease. Bright Peak’s optimized cytokine payload is engineered to uniquely augment binding to IL2Rα and ablate binding to IL2Rβ for the precise and potent activation of Treg over other immune cell types. Conjugation to a 30 kDa PEG generates a fully synthetic cytokine with optimal pharmacokinetic properties that is able to selectively expand Tregs in cynomolgus monkeys up to 60-fold and to strongly suppress antigen-specific T cell-mediated inflammation in mice. Based on these best-in-class properties, IND-enabling studies have been initiated and a first in human trial is planned to start early 2024.

Title: Identification of BPT323 – An immunocytokine for treatment of autoimmune diseases combining orthogonal modes of action of TNFα blockade and selective Treg expansion

Abstract Highlights: Bright Peak has developed a cell-free chemical protein synthesis and conjugation platform to rapidly generate optimized antibody-cytokine (immunocytokine, IC) therapeutics within weeks. We have site-specifically conjugated a single IL-2 variant that selectively activates and expands Tregs to the Fc region of the well-characterized anti-TNFα antibody adalimumab to generate an anti-TNFα-IL2 IC that fully retains the functions of the parent molecules in vitro and in vivo. TNFα-IL2 IC is apparently able to leverage an additional mode-of-action as its ability to activate and expand Tregs is augmented in the presence of TNFα. This suggests that TNFα-IL2 IC may exhibit higher local activity in inflamed tissues where TNFα is present at high levels.

The abstracts are available for viewing on Bright Peak’s website, www.brightpeaktx.com, and online at:

https://www.aegeanconferences.org/src/App/sessions/posters/155

About Bright Peak Therapeutics

Bright Peak is a privately held biotechnology company based in Basel, Switzerland and San Diego, CA. We are rapidly advancing a robust portfolio of next generation, multifunctional, cytokine-based immunotherapies for the treatment of patients with cancer and autoimmune disease. We accomplish this by leveraging our world class protein engineering capabilities and our unique cell-free technology platform to chemically synthesize and conjugate novel protein therapeutics that reflect state-of-the-art insights into cytokine and immune checkpoint biology. Our pipeline stretches from discovery to IND-enabling and encompasses enhanced cytokines, antibody-cytokine conjugates and other novel formats. Bright Peak is funded by a syndicate of leading healthcare investors.

Contact:

info@brightpeaktx.com

• The transaction reflects a pre-money equity value of $400 million for AUM Biosciences
• Transaction is expected to provide $69 million of gross proceeds (assuming no redemptions by Mountain Crest stockholders)
• Broad pipeline of drug candidates across multiple oncology programs; two lead clinical-stage candidates addressing a combined market opportunity of $10+ billion in metastatic colorectal cancer, and TRK Fusion and mutation cancers
• Mr. Vishal Doshi will continue to lead as the CEO of the publicly traded holding entity; a Mountain Crest representative will join the Board of Directors
• Company to expand US operations and clinical programs

SINGAPORE and NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) — AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical stage pipeline designed to deploy multi-faceted inhibition strategies to reverse cancer resistance, and Mountain Crest Acquisition Corp. V (Nasdaq: MCAG) (“Mountain Crest”), a publicly-traded special purpose acquisition company formed in Delaware, whose management team has an impressive pedigree of successful SPAC transactions, today announced that they have entered into a definitive business combination agreement (the “Agreement”). Upon closing of the transaction, the combined company will operate under a holding entity to be formed as a Cayman Islands exempted company (“Holdco”) and intends to trade on the Nasdaq Stock Market under the ticker symbol AUMB. The transaction reflects a pre-money equity value of $400 million for AUM and is expected to close in the first quarter of 2023. The transaction is expected to provide approximately $69 million of cash held in Mountain Crest’s trust account, assuming no redemptions.

AUM is advancing a broad portfolio of precision oncology therapeutics. AUM001 is a selective and synergistic MNK inhibitor as shown in current studies and expected to begin Phase 2 enrollment in the fourth quarter 2022. AUM601 is a promising therapy for TRK fusions and mutations within the kinase domain and is on track to enter Phase 2. AUM302 is a potentially first-in-class macrocyclic oral kinase inhibitor rationally designed small molecule to uniquely combine pan-PIM kinase, pan-PI3K and mTOR inhibition in a single agent. Comprised of pharma industry veterans with decades of research and development experience, the AUM leadership has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and has contributed to over 50 INDs and over 150 oncology clinical trials, and development of several currently marketed oncology treatments with annual peak sales up to $3 billion.

AUM completed a $27 million Series A funding round in 2021, and since then has demonstrated sustained growth, while partnering with major pharma companies and securing other non-dilutive funding sources such as grants in support of its development activity.

Upon closing of the transaction, Vishal Doshi, AUM’s CEO, will continue to lead Holdco as its CEO. Mr. Doshi, a pharmacist and medicinal chemist by background, is a seasoned leader with an extensive experience in commercial deal structuring valued at over $4 billion. He is also a Global Pharma Key Opinion Leader with the Korea Pharmaceutical Industry, a government-affiliated institution which provides professional and systematic support to develop domestic health industry and enhance health services.

Mr. Doshi commented, “Since our inception, we have worked to scientifically, commercially and financially de-risk our portfolio by leveraging our world class team, strong fundamentals, and un-paralleled executional track record. This merger allows AUM to further continue our focus on developing our scientifically differentiated portfolio. We are poised to achieve multiple development milestones over the next two years generating significant value for patients and investors.”

Dr. Suying Liu, Chairman, CEO and CFO of Mountain Crest, commented, “AUM is a unique and compelling investment opportunity, with its clinical-stage diversified pipeline of precision therapeutic candidates and global strategic partnerships with industry heavyweights, pointing to significant future growth potential and allowing the company to have a greater US footprint. I am thrilled to be partnering with Mr. Doshi and his exceptional team to bring their vision to fruition.”

AUM Investment Highlights

• AUM’s lead candidate AUM001 has shown highly selective inhibition of MNK 1/2 in current studies, which in turn, is expected to lead to inhibition of eIF4E phosphorylation. AUM expects to begin enrollment in the fourth quarter 2022 in a global Phase 2 trial of AUM001 as a monotherapy and in combination with anti-PD-1 therapy KEYTRUDA in metastatic colorectal cancer with a focus on the microsatellite stable subset, thereby seeking to render immunologically “cold” tumors “hot,” in collaboration with MSD, a tradename of Merck & Co., Inc. AUM has received authorization for the Investigational New Drug (IND) application from the U.S. Food and Drug Administration for this study (NCT05462236).
• AUM has also secured a partnership with Roche to develop AUM001 in combination with atezolizumab (Tecentriq^®), Roche’s anti-PD-L1 therapy, across multiple solid tumor indications.
• AUM is planning Phase 2 trials with AUM601, a potentially highly selective, oral small molecule designed to inhibit not only pan-TRK (TRKA, TRKB, and TRKC), but also resistance mutations of TRKs, by blocking the mutations that occur within the binding site. AUM601 was granted Orphan Drug Designation by the US FDA in September 2022.
• AUM is advancing IND enabling studies for AUM302, a potentially first-in-class macrocyclic oral kinase inhibitor rationally designed small molecule to uniquely combine pan-PIM kinase, pan-PI3K and mTOR inhibition in a single agent and AUM003, a potential blood brain barrier penetrating selective MNK inhibitor.
• AUM has sub-licensed the Greater China rights (AUM001, AUM302 and AUM003) to Newsoara making it eligible to receive up to $135 million in development, regulatory, and commercial milestones, plus up to double digit royalties.

Transaction Overview

As part of the transaction, (i) all outstanding AUM shares will be cancelled in exchange for approximately 40 million Holdco ordinary shares valued at $10 per Holdco share, subject to closing adjustments, (ii) each outstanding Mountain Crest unit will be automatically detached, (iii) each unredeemed outstanding share of Mountain Crest common stock will be cancelled in exchange for the right to receive one (1) Holdco ordinary share, (iv) every ten (10) outstanding Mountain Crest rights will be cancelled and cease to exist in exchange for one (1) Holdco ordinary share. Mountain Crest has not issued any warrants. The transaction is expected to provide approximately $69 million of cash held in Mountain Crest’s trust account, assuming no redemptions.

The Boards of Directors of each of Mountain Crest and AUM have approved the transaction. The transaction will require the approval of the stockholders of both Mountain Crest and AUM, and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The transaction is expected to close in the first quarter of 2023.

Additional information about the proposed transaction, including a copy of the Agreement, will be provided in a Current Report on Form 8-K to be filed by Mountain Crest with the Securities and Exchange Commission (the “SEC”) and will be available at www.sec.gov.

Advisors
Global Fund LLC is acting as M&A advisor to AUM. DLA Piper LLP (US) is serving as legal counsel to AUM. Loeb & Loeb LLP is serving as legal counsel to Mountain Crest.

About AUM Biosciences
AUM is a global clinical-stage oncology company focused on advancing a clinical stage pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. AUM is advancing a broad portfolio of precision oncology therapeutics. AUM001 is a selective and synergistic MNK inhibitor as shown in current studies and expected to begin Phase 2 enrollment in the fourth quarter 2022. AUM601 is a promising therapy for TRK fusions and mutations within the kinase domain and is on track to enter Phase 2 planning. AUM302 is a potentially first-in-class macrocyclic oral kinase inhibitor rationally designed small molecule to uniquely combine pan-PIM kinase, pan-PI3K and mTOR inhibition in a single agent. Comprised of pharma industry veterans with decades of research and development experience, the AUM leadership has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and has contributed to over 50 INDs and over 150 oncology clinical trials, and development of several currently marketed oncology treatments with annual peak sales up to $3 billion.

About Mountain Crest
Mountain Crest Acquisition Corp. V (Nasdaq: MCAG) is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Non-Solicitation
This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Important Information About the Proposed Business Combination and Where to Find It
In connection with the proposed business combination, AUM, Mountain Crest and/or a successor entity of the transaction intends to file relevant materials with the SEC, including a registration statement on Form F-4 containing a proxy statement/prospectus (the “Registration Statement”). The Registration Statement will include a proxy statement/prospectus to be distributed to holders of Mountain Crest’s common stock in connection with Mountain Crest’s solicitation of proxies for the vote by Mountain Crest’s stockholders with respect to the proposed transaction and other matters as described in the Registration Statement, as well as the prospectus relating to the offer of securities to be issued to AUM’s stockholders in connection with the proposed business combination. After the Registration Statement has been filed and declared effective, Mountain Crest will mail a definitive proxy statement, when available, to its stockholders. Copies of these documents may be obtained free of charge at the SEC’s website at www.sec.gov. Stockholders of Mountain Crest are urged to read the Registration Statement and the other relevant materials when they become available before making any voting decision with respect to the proposed business combination because they will contain important information. The information contained on, or that may be accessed through, the website referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

Participants in the Solicitation
Mountain Crest and its directors and executive officers may be deemed participants in the solicitation of proxies from Mountain Crest’s stockholders with respect to the business combination. A list of the names of those directors and executive officers and a description of their interests in Mountain Crest will be included in the Registration Statement for the proposed business combination and be available at www.sec.gov. Additional information regarding the interests of such participants will be contained in the Registration Statement for the proposed business combination when available. Information about Mountain Crest’s directors and executive officers and their ownership of Mountain Crest common stock is set forth in Mountain Crest’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such filing. Other information regarding the interests of the participants in the proxy solicitation will be included in the Registration Statement pertaining to the proposed business combination when it becomes available. These documents can be obtained free of charge from the sources indicated above.

AUM and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Mountain Crest in connection with the proposed business combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination will be included in the Registration Statement for the proposed business combination.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Mountain Crest’s and AUM’s actual results may differ from their expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Mountain Crest’s and AUM’s expectations with respect to future performance and anticipated financial impacts of the proposed business combination, the satisfaction of the closing conditions to the proposed business combination, and the timing of the completion of the proposed business combination.

These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside Mountain Crest’s and AUM’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change, or other circumstances that could give rise to the termination of the Agreement; (2) the outcome of any legal proceedings that may be instituted against Mountain Crest and AUM following the announcement of the Agreement and the transactions contemplated therein; (3) the inability to complete the proposed business combination, including due to failure to obtain approval of the stockholders of Mountain Crest and AUM, certain regulatory approvals, or satisfy other conditions to closing in the Agreement; (4) the occurrence of any event, change, or other circumstance that could give rise to the termination of the Agreement or could otherwise cause the transaction to fail to close; (5) the impact of the COVID-19 pandemic on AUM’s business and/or the ability of the parties to complete the proposed business combination; (6) the inability to obtain the listing of Holdco’s ordinary shares on Nasdaq following the proposed business combination; (7) the risk that the proposed business combination disrupts current plans and operations as a result of the announcement and consummation of the proposed business combination; (8) the ability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, competition, the ability of AUM to grow and manage growth profitably, and retain its key employees; (9) costs related to the proposed business combination; (10) changes in applicable laws or regulations; (11) the possibility that Mountain Crest or AUM may be adversely affected by other economic, business, and/or competitive factors; (12) risks relating to the uncertainty of the projected financial information with respect to AUM; (13) risks related to the organic and inorganic growth of AUM’s business and the timing of expected business milestones; (14) the amount of redemption requests made by Mountain Crest’s stockholders; and (15) other risks and uncertainties indicated from time to time in the final prospectus of Mountain Crest for its initial public offering and the Registration Statement relating to the proposed business combination, including those under “Risk Factors” therein, and in Mountain Crest’s other filings with the SEC. Mountain Crest cautions that the foregoing list of factors is not exclusive. Mountain Crest and AUM caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Mountain Crest and AUM do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based.

Contacts:

For AUM Biosciences Pte. Ltd.:
Mr. Vishal Doshi
CEO
10 Anson Road, 24-16 A/B, Singapore, 079903

For Mountain Crest Acquisition Corp. V:
Dr. Suying Liu
Chairman, CEO and CFO
311 W 43rd St, 12th Fl, New York, NY 10036, USA

Investors:
ICR Westwicke
Stephanie Carrington
T: (646) 277-1282
stephanie.carrington@westwicke.com

Media:
FINN Partners
Glenn Silver
T: (973) 818-8198
glenn.silver@finnpartners.com

SPAG/FINN
Verlynn Heng
+65-91861225
verlynn.heng@spag.asia

CNH Industrial: Periodic Report on the Buyback Program

London, October 19, 2022

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that under a first tranche of $50 million share buyback (the “Tranche”) in the framework of its $300 million common share buyback program, the Company completed transactions during the period October 10 – October 14, reported in aggregate, based on automatic orders placed with the Company’s broker (who has made its trading decisions as to the timing of the purchases independently of the Company and on the basis of instructions given before the commencement of the Company’s closed period under the applicable regulations) as follows:

Date	Number of common shares purchased	Average price per share excluding fees	Consideration excluding fees	Consideration (*) excluding fees
		(€)	(€)	($)
October 10, 2022	5,361	11.9902	64,279.46	62,331.79
October 11, 2022	200,000	12.0482	2,409,640.00	2,342,892.97
October 12, 2022	200,000	12.0014	2,400,280.00	2,329,711.77
October 13, 2022	2,599	11.8586	30,820.50	30,016.09
October 14, 2022	187,236	12.5189	2,343,988.76	2,277,653.88
	595,196	–	7,249,008.72	7,042,606.50

(*) All translations determined from Euro to US Dollar at the exchange rate reported by the European Central Bank on the date of each purchase.

After the purchases announced today and considering those previously executed under the Tranche, the total invested amount is approximately €32,049,286.15 ($31,414,451.36) for a total amount of 2,685,676 common shares purchased.

As of October 14, 2022, the Company held 18,900,339 common shares, net of the common shares already delivered to fulfill its obligations arising from equity incentive plans.

Details of the transactions described in the table above, including the regulated markets where the purchases were made, are available on the Company’s corporate website under the Buyback Programs section at the following address: bit.ly/CNHI_Buyback.

CNH Industrial (NYSE: CNHI / MI: CNHI) is a world-class equipment and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Productivity, the Company provides the strategic direction, R&D capabilities, and investments that enable the success of its global and regional Brands. Globally, Case IH and New Holland Agriculture supply 360° agriculture applications from machines to implements and the digital technologies that enhance them; and CASE and New Holland Construction Equipment deliver a full lineup of construction products that make the industry more productive. The Company’s regionally focused Brands include: STEYR, for agricultural tractors; Raven, a leader in digital agriculture, precision technology and the development of autonomous systems; Flexi-Coil, specializing in tillage and seeding systems; Miller, manufacturing application equipment; Kongskilde, providing tillage, seeding and hay & forage implements; and Eurocomach, producing a wide range of mini and midi excavators for the construction sector, including electric solutions. Across a history spanning over two centuries, CNH Industrial has always been a pioneer in its sectors and continues to passionately innovate and drive customer efficiency and success. As a truly global company, CNH Industrial’s 37,000+ employees form part of a diverse and inclusive workplace, focused on empowering customers to grow, and build, a better world.

For more information and the latest financial and sustainability reports visit: cnhindustrial.com

For news from CNH Industrial and its Brands visit: media.cnhindustrial.com

Contacts:

Media Relations
Email: mediarelations@cnhind.com

Investor Relations
Email: investor.relations@cnhind.com

Attachment

• 20221019_PR_CNH_Industrial_Buyback_Periodic_Report

เมืองควิเบก, Oct. 20, 2022 (GLOBE NEWSWIRE) — LeddarTech® ผู้นำระดับโลกในการให้บริการเทคโนโลยีการตรวจจับ ADAS และ AD ที่ยืดหยุ่น แข็งแกร่ง และแม่นยำที่สุด ยินดีที่จะประกาศการเข้าร่วมในงานสำคัญด้านยานยนต์ในเมืองดีทรอยต์ รัฐมิชิแกนจำนวนสองงาน โดยจะสาธิตLeddarVisionการฟิวชันการตรวจจับข้อมูลดิบและโซลูชันการรับรู้อันเป็นเอกลักษณ์ที่ช่วยในการนำ ADAS และโซลูชันการขับขี่อัตโนมัติออกใช้งานในวงกว้าง

ทีมเทคนิคและผู้บริหารของ LeddarTech เฝ้ารอเวลาในการนำเทคโนโลยีของบริษัทออกสาธิตในงานที่กำลังจะจัดขึ้นทั้งสองงานนี้:

American Automotive Summit – 1-2 พฤศจิกายน – MGM Grand Detroit

American Automotive Summit เป็นเวทีประจำปีที่ใช้เพื่อแลกเปลี่ยนความคิดเห็นเกี่ยวกับผลกระทบของการเปลี่ยนแปลงในตลาดและเทคโนโลยีใหม่ ๆ สำหรับผู้นำด้านยานยนต์ทั้งในปัจจุบันและอนาคต คุณจะได้สร้างเครือข่ายกับเพื่อนของคุณมากกว่า 150 ราย สร้างสัมพันธ์กับผู้แสดงสินค้า รวมถึงเรียนรู้จากผู้มีอิทธิพลในอุตสาหกรรมและผู้บริหารระดับสูงที่เกี่ยวข้องกับการผลิต การปฏิบัติการ การออกแบบ วิศวกรรม คุณภาพของห่วงโซ่อุปทาน และนวัตกรรม

• การนำเสนอของคุณ Frantz Saintellemy ประธานและ COO ของ LeddarTech เวลา 12:10 น. ตามเวลา EST ในวันที่ 2 พฤศจิกายน

  หัวข้อ: “เทคโนโลยีการตรวจจับและการรับรู้ – ความท้าทายและโซลูชันที่สำคัญสำหรับ ADAS และ AD”

  ในการนำเสนอนี้ คุณจะได้เรียนรู้เกี่ยวกับการเปลี่ยนผ่านไปสู่ยานพาหนะที่ใช้ซอฟต์แวร์ในการทำงาน รวมถึงบทบาทของเทคโนโลยีการตรวจจับและการรับรู้ในตัวยานพาหนะ

• บูธ LeddarTech: 9

  ขอเข้าพบปะกับ LeddarTech ที่งาน

Tech.AD USA – 13-15 พฤศจิกายน – The Henry Hotel Detroit

Tech.AD USA เป็นแพลตฟอร์มแลกเปลี่ยนความรู้ชั้นนำในอเมริกาเหนือ ที่ประกอบด้วยผู้มีส่วนได้ส่วนเสียที่มีบทบาทอย่างแข็งขันในด้านระบบอัตโนมัติของยานพาหนะกว่า 250 ราย

LeddarTech นำเสนอ: LeddarVision เทคโนโลยีการฟิวชันเซ็นเซอร์ข้อมูลดิบและการรับรู้

• บูธแสดงสินค้าของ LeddarTech: 1
  ผู้เชี่ยวชาญทางเทคนิคของเราจะสาธิตให้คุณเห็นว่า เทคโนโลยีการฟิวชันข้อมูลดิบจะสามารถช่วยลดชุดเซ็นเซอร์ที่แสนซับซ้อนและขจัดการใช้ฮาร์ดแวร์ เพื่อให้ลูกค้ามีความยืดหยุ่นในการปรับขนาดและส่งมอบ ADAS และ AD ที่มีประสิทธิภาพมากขึ้นได้อย่างรวดเร็วได้อย่างไร

• ถ่ายทอดสด รถทดลอง LeddarCar บนถนน
  การสัมผัสประสบการณ์การใช้งานซอฟต์แวร์อันเป็นหนึ่งเดียวของเรา ซึ่งช่วยมอบความอิสระระดับ 2-5 ในโลกแห่งความจริงนี้มีที่นั่งจำกัด

  ซัพพลายเออร์ยานยนต์ระดับ 1-2 และ OEM: จองการสาธิต LeddarCar

เกี่ยวกับ LeddarTech

LeddarTech ก่อตั้งขึ้นในปี 2007 โดยเป็นบริษัทซอฟต์แวร์ AD (ขับขี่อัตโนมัติ) และ ADAS (ระบบช่วยเหลือผู้ขับขี่ขั้นสูง) สำหรับยานยนต์ที่นำเสนอโซลูชันการฟิวชันข้อมูลดิบและการรับรู้แบบครบวงจร ที่ช่วยให้ลูกค้าสามารถแก้ปัญหาความท้าทายที่สำคัญได้ตลอดทั้งห่วงโซ่คุณค่า

เทคโนโลยีซอฟต์แวร์ระดับยานยนต์ของ LeddarTech มีชื่อว่า LeddarVision เป็นโซลูชันที่ยืดหยุ่น แข็งแกร่ง คุ้มราคา และใช้ข้อมูลจากเซ็นเซอร์ ซึ่งสามารถนำเสนอแบบจำลองสภาพแวดล้อม 3 มิติที่มีความแม่นยำสูงได้ ซอฟต์แวร์ที่ปรับขนาดได้นี้รองรับความอิสระของ SAE ในทุกระดับด้วย AI และอัลกอริธึมคอมพิวเตอร์วิทัศน์เพื่อผสานข้อมูลดิบจากเซ็นเซอร์ที่ใช้ในแอปพลิเคชัน L2-L5 การใช้งานการผสานข้อมูลดิบของ LeddarTech ช่วยให้สามารถตรวจจับสิ่งกีดขวางขนาดเล็กมากบนท้องถนน ด้วยอัตราการตรวจจับที่ดีกว่าและมีสัญญาณเตือนลวงน้อยกว่าโซลูชัน “การฟิวชันวัตถุ” แบบเดิม นอกจากนี้ ระบบยังสามารถตรวจจับสิ่งกีดขวางแบบไม่จำแนกประเภทได้อีกด้วย ซึ่งจะช่วยเพิ่มความปลอดภัยให้กับยานยนต์ไปอีกขั้นหนึ่ง

LeddarTech เป็นผู้รับผิดชอบในการคิดค้นนวัตกรรมใหม่ ๆ ในแอปพลิเคชันด้านยานยนต์และการเคลื่อนที่ระยะไกลที่ทันสมัย ด้วยเทคโนโลยีทั้งที่จดสิทธิบัตรแล้วหรือที่รอการอนุมัติมากกว่า 140 รายการ ที่ช่วยเสริมขีดความสามารถ ADAS และการขับขี่แบบอัตโนมัติ

ดูข้อมูลเพิ่มเติมเกี่ยวกับ LeddarTech ได้ที่ www.leddartech.com และที่ LinkedIn, Twitter, Facebook และ YouTube

ติดต่อ:
Daniel Aitken รองประธานบริษัทฝ่ายการตลาดโลก ฝ่ายผู้ลงทุนและการสื่อสารสัมพันธ์ LeddarTech Inc.
โทร: + 1-418-653-9000 ต่อ 232 daniel.aitken@leddartech.com

รายชื่อติดต่อผู้ลงทุนสัมพันธ์: InvestorRelations@leddartech.com
https://investors.leddartech.com/

Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, LeddarEcho, VAYADrive, VayaVision, XLRator และโลโก้ที่เกี่ยวข้องเป็นเครื่องหมายการค้าหรือเครื่องหมายการค้าจดทะเบียนของ LeddarTech Inc. และบริษัทในเครือ แบรนด์ ชื่อผลิตภัณฑ์ และเครื่องหมายอื่น ๆ ทั้งหมดเป็นหรืออาจเป็นเครื่องหมายการค้าหรือเครื่องหมายการค้าจดทะเบียนที่ใช้เพื่อระบุผลิตภัณฑ์หรือบริการของเจ้าของที่เกี่ยวข้อง

รูปภาพประกอบของการแถลงนี้สามารถรับชมได้ที่ https://www.globenewswire.com/NewsRoom/AttachmentNg/982d222e-d193-4c43-a508-d3621411c300

SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) — On Oct. 19, 2022, the Japan Coast Guard (JCG) commenced flight operations using an MQ-9B SeaGuardian^® Remotely Piloted Aircraft (RPA) from General Atomics Aeronautical Systems, Inc. (GA-ASI). JCG is operating the SeaGuardian from the Japan Maritime Self Defense Force (JMSDF) Air Station Hachinohe. The RPA will primarily perform Maritime Wide Area Search (MWAS) over the Sea of Japan and the Pacific Ocean. Other missions will include search and rescue, disaster response, and maritime law enforcement.

“SeaGuardian is the world’s premier asset for performing MWAS,” said Robert Schoeffling, vice president of International Strategic Development at GA-ASI. “We’re proud to support the Government of Japan’s policy to strengthen its maritime security.”

SeaGuardian features a multi-mode maritime surface-search radar with an Inverse Synthetic Aperture Radar (ISAR) imaging mode, an Automatic Identification System (AIS) receiver, and High-Definition – Full-Motion Video sensor equipped with optical and infrared cameras. This sensor suite enables real-time detection and identification of surface vessels over thousands of square nautical miles and provides automatic tracking of maritime targets and correlation of AIS transmitters with radar tracks.

GA-ASI’s MQ-9B SkyGuardian^® and SeaGuardian are revolutionizing the long-endurance RPAS market by providing all-weather capability and full compliance with STANAG-4671 (NATO UAS airworthiness standard). This feature, along with our operationally proven, collision-avoidance radar, enables flexible operations in civil airspace.

SkyGuardian and SeaGuardian have garnered significant interest from customers throughout the world. The UK Ministry of Defence selected MQ-9B SkyGuardian for its Protector program, and the Belgian Ministry of Defense signed a contract for SkyGuardian.

About GA-ASI

General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable Remotely Piloted Aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator^® RPA series and the Lynx^® Multi-mode Radar. With more than seven million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com.

SkyGuardian, SeaGuardian, Predator and Lynx are registered trademarks of General Atomics Aeronautical Systems, Inc.

Contact Information:
GA-ASI Media Relations
GA-ASI Media Relations
asi-mediarelations@ga-asi.com
+1 (858) 524-8101

Related Images

Image 1

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Featured Image for General Atomics Aeronautical Systems, Inc.